Last week, Allergan (NYSE:AGN) said that it filed lawsuits against Imprimis Pharmaceuticals (NSDQ:IMMY), Prescriber’s Choice and Sincerus Florida, claiming that the companies manufacture, sell and promote unapproved new drugs. The pharmaceutical giant filed suit in the U.S. District Court for the Central District of California. Today, Imprimis fired back at Allergan, denying the allegations and saying that […]
Imprimis, Precision Lens sign marketing and sales agreement
Imprimis Pharmaceuticals (NSDQ:IMMY) said today that it signed a 3-year exclusive sales agreement with Precision Lens. According to the deal, Precision Lens plans to deploy a sales team to expand Imprimis’ ophthalmic portfolio in 13 states across the U.S. Midwest. Precision Lens said it will sell San Diego-based Imprimis’ Dropless Therapy, LessDrops combination eye drops […]
Imprimis touts ‘dropless therapy’ study for cataract surgery
Imprimis Pharmaceuticals (NSDQ:IMMY) touted data today from a peer-reviewed study of patients who received its “dropless therapy” following cataract surgery. The San Diego-based company uses a compounded antibiotic and steroid formulation in single, injectable doses administered by physicians following ocular surgery. The treatment is designed to eliminate the need for patient-administered eye drops, potentially eliminating patient […]
